Ignite Creation Date:
2024-05-06 @ 8:10 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06280716
Status:
RECRUITING
Last Update Posted:
2024-06-21
First Post:
2024-02-20
Brief Title:
A Study of Lebrikizumab LY3650150 WithWithout Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Multicenter Randomized Double-Blind Placebo-controlled Phase 3 Trial to Investigate the Efficacy and Safety of Lebrikizumab When Used WithWithout Topical Corticosteroid Treatment in Participants With Moderate-To-Severe Atopic Dermatitis
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab withwithout Topical Corticosteroid Treatment in Participants with Moderate-to-Severe Atopic Dermatitis The study will last approximately 62 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| J2T-MC-KGBW | OTHER | Eli Lilly and Company | None |